31794-45-3

Usage

Uses

Used in Polymer and Resin Industry:
3-Oxo-3,4-Dihydro-2H-1,4-Benzoxazine-6-Sulfonyl Chloride is used as a component in the synthesis of polymers and resins for its heat-resistant properties, which are crucial in applications requiring materials with high thermal stability.
Used in Organic Synthesis:
3-Oxo-3,4-Dihydro-2H-1,4-Benzoxazine-6-Sulfonyl Chloride is used as a sulfonylating agent in organic synthesis, facilitating the introduction of a sulfonyl group into molecules, which can be important for the development of new chemical compounds with specific properties.
Note: Due to the lack of specific information provided in the materials, the uses listed above are speculative based on the compound's structure and typical applications of similar compounds. For detailed and accurate applications, further research in chemical databases or scientific literature is recommended.

InChI:InChI=1/C8H6ClNO4S/c9-15(12,13)5-1-2-7-6(3-5)10-8(11)4-14-7/h1-3H,4H2,(H,10,11)

Upstream product

• 5466-88-6 3,4-dihydro-3-oxo-2H-1,4-benzoxazine 
• 89976-75-0 6-amino-2H-1,4-benzoxazin-3(4H)-one 
• 95-55-6 2-amino-phenol 

Downstream Products

• 27320-80-5 6-Sulfamoyl-2H-1,4-benzoxazin-3-on 
• 891908-74-0 N-(3,4-dimethylphenyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-sulfonamide 
• 56077-77-1 6-Mercapto-2,3-dihydro-1,4-benzoxazinon-3 
• 1214250-15-3 5-[benzyl-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonyl)-amino]-2-fluoro-N-isopropyl-benzamide 

Relevant academic research and scientific papers

Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

Described herein are methods for using compounds that activate pyruvate kinase.

BICYCLIC PKM2 ACTIVATORS

Compounds and compositions comprising compounds including formula (I) that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.

ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, A, B, D, E, G, Ar, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS

Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.